614 related articles for article (PubMed ID: 16443309)
41. Induction of Tc1 response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg.
Huang Y; Chen Z; Jia H; Wu W; Zhong S; Zhou C
Clin Immunol; 2006 Jun; 119(3):280-90. PubMed ID: 16531121
[TBL] [Abstract][Full Text] [Related]
42. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy.
Tuettenberg A; Jonuleit H; Tüting T; Brück J; Knop J; Enk AH
Gene Ther; 2003 Feb; 10(3):243-50. PubMed ID: 12571632
[TBL] [Abstract][Full Text] [Related]
43. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
44. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
Ishii S; Hiroishi K; Eguchi J; Hiraide A; Imawari M
Gene Ther; 2006 Jan; 13(1):78-87. PubMed ID: 16107857
[TBL] [Abstract][Full Text] [Related]
45. TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice.
Zhang W; Yang H; Wang Z; Jim X
Chin Med J (Engl); 2002 Dec; 115(12):1767-71. PubMed ID: 12622920
[TBL] [Abstract][Full Text] [Related]
46. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
47. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination.
Steitz J; Tormo D; Schweichel D; Tüting T
Cancer Gene Ther; 2006 Mar; 13(3):318-25. PubMed ID: 16151477
[TBL] [Abstract][Full Text] [Related]
48. Induction of antitumor immunity using bone marrow-generated dendritic cells.
Porgador A; Snyder D; Gilboa E
J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
[TBL] [Abstract][Full Text] [Related]
49. Dendritic cell generated from CD34+ hematopoietic progenitors can be transfected with adenovirus containing gene of HBsAg and induce antigen-specific cytotoxic T cell responses.
Yang JY; Cao DY; Liu WC; Zhang HM; Teng ZH; Ren J
Cell Immunol; 2006 Mar; 240(1):14-21. PubMed ID: 16875681
[TBL] [Abstract][Full Text] [Related]
50. [Investigation on specific killing acute leukemia cell reaction of the cytotoxic T lymphocyte induced by dendritic cell pulsed with frozen-thawed antigen].
He B; Qiu G; Xie X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Dec; 21(6):974-8. PubMed ID: 15646345
[TBL] [Abstract][Full Text] [Related]
51. [In vitro anti-tumor effect of CTL induced by HSP70-Id complex-modified dendritic cells].
Wang ZH; Ye Q; Hu ZQ; Ye ZQ; Yu X; Shen GX
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):481-5. PubMed ID: 17147108
[TBL] [Abstract][Full Text] [Related]
52. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
Chan T; Sami A; El-Gayed A; Guo X; Xiang J
Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
[TBL] [Abstract][Full Text] [Related]
53. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
[TBL] [Abstract][Full Text] [Related]
54. Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes.
Pajtasz-Piasecka E; Rossowska J; Szyda A; Krawczenko A; Dus D
Oncol Rep; 2007 May; 17(5):1249-57. PubMed ID: 17390073
[TBL] [Abstract][Full Text] [Related]
55. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H
Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908
[TBL] [Abstract][Full Text] [Related]
56. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
[TBL] [Abstract][Full Text] [Related]
57. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
58. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
59. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation.
Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; van der Burg SH; Offringa R
Eur J Immunol; 2008 Apr; 38(4):1033-42. PubMed ID: 18350546
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
Yang S; Darrow TL; Vervaert CE; Seigler HF
Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
